A carregar...
Comparison of Abiraterone Acetate Versus Ketoconazolein Patients with Metastatic Castration Resistant Prostate Cancer Refractory to Docetaxel
BACKGROUND: Abiraterone, a potent CYP 17 inhibitor, is standard treatment in docetaxel refractory, metastatic castrate resistant prostate cancer (mCRPC). However, in countries where abiraterone has not been approved yet, or for patients who cannot afford it, ketoconazole is used as an alternative CY...
Na minha lista:
| Publicado no: | Prostate |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4696030/ https://ncbi.nlm.nih.gov/pubmed/24338986 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.22765 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|